• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population ‐Based Retrospective Cohort Study From the United Kingdom
ConclusionCardiovascular morbidity was increased among patients with TAK receiving primary care services in the UK. Treatment with statins and antiplatelet agents in these patients was suboptimal.
Source: Arthritis and Rheumatology - February 27, 2021 Category: Rheumatology Authors: Ruchika Goel, Joht Singh Chandan, Rasiah Thayakaran, Nicola J. Adderley, Krishnarajah Nirantharakumar, Lorraine Harper Tags: Full Length Source Type: research

Cardiovascular and renal morbidity in Takayasu arteritis: a population ‐based retrospective cohort study from UK
ConclusionCardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti ‐platelets in these patients was suboptimal.
Source: Arthritis and Rheumatology - September 22, 2020 Category: Rheumatology Authors: Ruchika Goel, Joht Singh Chandan, Rasiah Thayakaran, Nicola J Adderley, Krishnarajah Nirantharakumar, Lorraine Harper Tags: FULL LENGTH Source Type: research

A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J. F. Belch, Deborah P. M. Symmons, on behalf of the TRACE RA Consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Pete Tags: Original Article Source Type: research

Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie‐Ju Hwang, Mary G. Boy, Pinaki Biswas, Iain B. McInnes Tags: Full Length Source Type: research

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research